Nose virus may explain brain fog in long COVID
NCT ID NCT05220241
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 51 adults who had COVID-19 2 to 12 months earlier and still had brain fog or other thinking problems. Researchers checked if the virus was still hiding in the nose's smell center. They compared these patients to a control group to see if lingering virus is linked to ongoing cognitive symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
51 people
The number who actually took part.
- Started
-
Jul 2022
- Finished
-
Jul 2025
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Common to cases and controls: * Age ≥ 18 years old and \<60 years old * Good oral and written command of French * Level of education ≥ 7 years of schooling * Initial episode of COVID-19 within 2 to 12 months * Symptomatic initial episode of COVID-19 * Initial symptoms not explained by another diagnosis * Initial episode documented by RT-PCR positive for SARS-CoV-2 and / or positive antigen test and / or positive serology (in the absence of vaccination) * Express consent to participate in the study * Affiliate or beneficiary of a social security scheme Case group: * Presence of at least one of the initial symptoms beyond 4 weeks following the onset of the acute phase of the disease * Prolonged symptoms not explained by another diagnosis with no known link to COVID-19 * Neurocognitive complaint (s) previously objectified by a neurologist and after completion of a neuro-psychological assessment * Impact of neurocognitive disorders on daily life authenticated by a Glasgow outcome scale extended ≤ 7 (see appendix 1) * Evolution of complaints for 2 to 12 months compared to the date of their first appearance Exclusion Criteria: Exclusion criteria common to cases and controls: * Person benefiting from a legal protection measure * Pregnant or breastfeeding woman * At least one neurological pathology among: * encephalopathy * encephalitis * severe neurological form of the initial episode of COVID-19 * neurodegenerative disease * History of stroke * Serious psychiatric history * Known nasal sinus pathology * Hemostatic disorder * Taking aspirin in the 15 days preceding the sample * Treatment with anticoagulants * Known allergy to lidocaine Secondary exclusion criteria for controls: \- Positive SARS-CoV-2 RT-PCR on nasopharyngeal sample on the day of inclusion
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cognitive disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Fondation A. de Rothschild
Paris, 75019, France
-
Hôpital Lariboisière-Fernand-Widal
Paris, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill stop COVID-19 before it starts?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
- The household maze: how does COVID-19 move between family members?
- New mRNA booster shot put to the test against comirnaty
- Can a second janssen shot cut severe COVID-19 in south africa?
- Can new vaccines outsmart COVID-19 variants?